Pipeline

MFA011 is a fusion antibody with MediMabBio’s proprietary anti-TIGIT antibody and IL15 cytokines. Conjugating IL15 to immune-cell-directed antibody enables targeted delivery of IL-15 to tumor sites. With increased efficacy and lowered toxicity, MFA011 has the potential to widen the therapeutic window of IL-15 therapy.

• Strong activation of tumor-fighting NK and T cell function through high affinity to IL-15 receptor
• Reduced loss of IL-15 to the cytokine sink
• Increased half-life with increased molecular weight
• Potent tumor growth suppression and safe in vivo